With contributions from world-renowned experts in metabolism, the textbook is the first to extensively analyze and illustrate techniques for use in early phase clinical studies of new drugs for diabetes, obesity and related cardiometabolic disease
SAN DIEGO, January 22, 2015 /PRNewswire/ – Profil Institute for Clinical Research, Inc., a clinical research organization (CRO) focused on diabetes and obesity, announced today a new textbook, Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development, edited by Profil Institute senior scientists Prof. Andrew Krentz, Prof. Lutz Heinemann and Dr. Marcus Hompesch and published by Springer, a leading global scientific publisher.
The textbook is the first to extensively analyze and illustrate techniques for use in early phase clinical studies of new drugs for diabetes, obesity and related cardiometabolic disease. The first portion of the book involving several chapters is a critical review of current clinical investigation methodologies. Each chapter focuses on a specific approach or methodology, written by a leading expert providing practical applications and scrutinizing pros and cons. The second portion of the book details emerging and complementary research methods, as well as related ethical and regulatory considerations.
Authors include scientists from Profil Institute; Helmholtz Zentrum München, Deutsches Forschungszentrum für Gesundheit und Umwelt; Image Reading Center, Inc.; Kinexum, Inc.; Kinmed, Inc.; Maastricht University Medical Centre; National Institutes of Health; University of California, San Diego; and University of Florida, Orlando. A list of chapters and authors is available on the Springer website.
“The editors of this book are all highly experienced experts in academic research and drug development, and they have recruited world leaders in metabolic research to cover a range of topics. Each chapter focuses on a specific approach or methodology, representing the leading edge of knowledge in clinical research and early stage drug development,” said Jerrold M. Olefsky, MD, University of California, San Diego, Professor of Medicine, Associate Dean for Scientific Affairs. “The textbook will be a valuable resource to anyone in the field of early phase metabolic research, as well as clinicians practicing in these specialties.”
About Profil Institute for Clinical Research, Inc.
Profil Institute for Clinical Research, Inc. is a science driven, early phase clinical research organization (CRO) focused on diabetes and obesity. It is renowned for its scientific expertise, depth of services, expanded scope of research methodologies, and experience with every clinically relevant drug class in diabetes. The company provides end-to-end early phase services from consulting for strategic clinical development and regulatory planning through design and completion of complex clinical trials, including the reporting and publication of final study results.
Profil Institute’s expertise and experience encompasses small and large molecule therapies, biologics and biosimilars through all routes of administration, as well as devices. The company’s clients range from large pharma and drug discovery companies to small virtual companies throughout the Americas, Europe and Asia.
Profil Institute is also recognized internationally as an innovator of methodologies to improve the quality of metabolic research, including its Automated Glucose Clamp technology. As the leading early phase CRO focused on diabetes and obesity, Profil Institute is driving new, higher standards in metabolic clinical research through collaborative science with key academic and industry partners and its Metabolic Research Partners™ program.
For further information, please contact: